| Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity | Immunity |  | | 2026 | 50 | 44 |
|
| Spatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer | Nature communications | | | 2026 | 12 | 15 |
|
| Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer | JCO precision oncology | | | 2025 | 23 | 94 |
|
| Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix | Gynecologic oncology reports | | | 2024 | 105 | 92 |
|
| Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting : final analysis of LUCY | Breast cancer research and treatment | | | 2024 | 109 | 687 |
|
| Identification of clinically relevant t cell receptors for personalized t cell therapy using combinatorial algorithms | Nature biotechnology | | | 2024 | 169 | 90 |
|
| Ovarian stimulation with letrozole in nulliparous young women with relapsing early-stage serous borderline ovarian tumors | Gynecologic oncology reports | | | 2024 | 20 | 52 |
|
| Assessment of chemical stability of monoclonal antibody and antibody drug conjugate administered by pressurized intraperitoneal aerosol chemotherapy | Journal of pharmaceutical and biomedical analysis | | | 2024 | 33 | 24 |
|
| Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma | Nature communications | | | 2024 | 74 | 58 |
|
| H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours | Nature communications | | | 2024 | 142 | 83 |
|
| Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon : a retrospective study | Swiss medical weekly | | | 2023 | 67 | 60 |
|
| Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity | BMJ open | | | 2023 | 500 | 117 |
|
| Changes of health-related quality of life 6 months after high-risk oncological upper gastrointestinal and hepatobiliary surgery: a single-centre prospective observational study (ChangeQol Study) | BMJ open | | | 2023 | 169 | 306 |
|
| Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics | International journal of cancer | | | 2023 | 516 | 109 |
|
| The clinical challenges of homologous recombination proficiency in ovarian cancer : from intrinsic resistance to new treatment opportunities | Cancer drug resistance | | | 2023 | 92 | 46 |
|
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | | 2022 | 245 | 208 |
|
| Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels | Revue médicale suisse | | | 2022 | 167 | 126 |
|
| Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer | Seminars in cancer biology | | | 2021 | 55 | 57 |
|
| Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer | Cancer Cell | | | 2021 | 298 | 444 |
|
| Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? | Cancer treatment reviews | | | 2021 | 77 | 288 |
|
| Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes | Scientific Reports | | | 2020 | 338 | 387 |
|
| Pathogenesis of ovarian cancer | | | | 2020 | 784 | 758 |
|
| Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation | Gynecologic Oncology Reports | | | 2020 | 292 | 253 |
|
| Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets — a narrative review | Annals of translational medicine | | | 2020 | 212 | 299 |
|
| BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients | Breast Cancer Research and Treatment |  | | 2019 | 445 | 3 |
|
| Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors | The Journal of Pathology | | | 2018 | 897 | 6 |
|
| High grade serous ovarian carcinomas originate in the fallopian tube | Nature Communications | | | 2017 | 531 | 562 |
|
| Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer | Journal of Translational Medicine | | | 2017 | 484 | 209 |
|
